Microsatellite instability (MSI) and the tumor mutation burden (TMB) as biomarkers of response to immune checkpoint inhibitors in prostate cancer

Journal article

Open access

Translational cancer research, Vol.14(5), pp.2553-2557

05/30/2025

DOI: 10.21037/tcr-2024-2516

PMCID: PMC12170210

PMID: 40530111

Files and links (1)

url

https://doi.org/10.21037/tcr-2024-2516View

Published (Version of record) Open Access

Editorial commentary

Title: Subtitle: Microsatellite instability (MSI) and the tumor mutation burden (TMB) as biomarkers of response to immune checkpoint inhibitors in prostate cancer
Creators: Ioannis A. Voutsadakis
Resource Type: Journal article
Publication Details: Translational cancer research, Vol.14(5), pp.2553-2557
DOI: 10.21037/tcr-2024-2516
PMID: 40530111
PMCID: PMC12170210
NLM abbreviation: Transl Cancer Res
ISSN: 2218-676X
eISSN: 2219-6803
Publisher: AME PUBLISHING COMPANY
Language: English
Date published: 05/30/2025
Academic Unit: Internal Medicine
Record Identifier: 9984825799902771

33 Record Views